Safety and Efficacy Clinical Study of SNS-595 for Second-Line Therapy in Patients With Advanced NSCLC

Summary

The purpose of this study is to evaluate the objective tumor response rate (based on the RECIST criteria) to SNS-595 as a second-line therapy in patients with advanced NSCLC.

Timeline

Start

2005-12-27

Primary completion

2007-03-05

Completion

2007-11-29

Drugs

Indications